Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Urethral cancer
Stage/Subtype:  recurrent urethral cancer
Trial Type:  Treatment
Results 1-20 of 20 for your search:
Start Over
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy
Status: Not yet active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: ML29725, NCI-2015-01995, NCT02589717
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15679, NCI-2015-02085, 2014-003655-66, I4T-MC-JVDC, NCT02426125
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: INCB 54828-101, NCI-2015-00611, NCT02393248
Radiation Therapy in Preventing Brain Metastases in Patients with Locally Advanced or Metastatic Bladder or Urinary Tract Cancer Previously Treated with Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2007-0933, NCI-2012-01675, NCT00756639
Pazopanib Hydrochloride and Paclitaxel in Treating Patients with Refractory Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BLDR0010, NCI-2011-00416, NCT01108055
Tesetaxel for Previously Treated Patients With Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TOBL204, NCI-2011-02438, NCT01215877
Gemcitabine Hydrochloride, Cisplatin, and Ipilimumab as First-Line Therapy in Treating Patients With Metastatic Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-148, NCI-2013-00250, 1110007307, NCT01524991
Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-0540/ 1200.171, NCI-2014-00859, 13-0540, NCT02122172
Palbociclib in Treating Patients with Metastatic Urothelial Cancer after First-Line Chemotherapy Failure
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1406, NCI-2015-00532, 14-2196, WI187190, NCT02334527
A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: B-701-U21, NCI-2015-00701, NCT02401542
Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-126, NCI-2015-01786, NCT02553642
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8808, NCI-2011-02500, CDR0000700997, UPCI 10-115, NCT01366144
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AGS15E-13-1, NCI-2013-02093, NCT01963052
Enzalutamide in Combination with Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Locally Advanced or Metastatic Stage IV Bladder Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-17924, NCI-2015-00231, NCT02300610
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients with Previously Treated Advanced or Metastatic Urothelial Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#252, NCI-2015-00426, NCT02437370
Cabozantinib-s-malate and Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Genitourinary Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9681, NCI-2014-02379, 150160, P141706, 15-C-0160, NCT02496208
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PM60184-A-003-14, NCI-2015-01510, 2014-002943-16, NCT02533674
A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29779, NCI-2015-02171, 2015-001741-88, NCT02471846
Genomic Based Assignment of Therapy in Treating Patients with Progressive Metastatic Urothelial Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: P152399, NCI-2016-00966, 16-C-0121, NCT02788201
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Start Over